We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Pericardial Tissue Valves Show Long-Term Stability

By HospiMedica staff writers
Posted on 13 Aug 2001
A multicenter study has shown that patients who received a pericardial tissue heart valve to replace their malfunctioning aortic valve have experienced excellent long-term results 17 years after implantation, with low overall complication rates. More...
The study was presented by Dr. Michael K. Branbury of The Cleveland Clinic Foundation (OH, USA) at the first biennial meeting of the Society for Heart Valve Disease in London (UK).

The study involved 267 patients who received valve implants in 1981 and 1983 and have been evaluated annually since that time. Among the parameters the researchers measured were left ventricular volume, pressure gradients across the valve, velocity, size of the valve's opening, and the presence of any aortic regurgitation. Patients were also evaluated for long-term improvements or declines. This assessment showed that while many patients preoperatively had been given the most severe classification, more than half have experienced a sustained improvement of one to two levels.

The valve implants received by all the patients in the study were the Carpentier-Edwards Perimount heart valve made of bovine pericardium, from Edwards Lifesciences Corp. (Irvine, CA, USA). "The Carpentier-Edwards aortic pericardial bioprosthesis demonstrates excellent hemodynamic stability over 17 years, with acceptable long-term transvalvular gradients and mild aortic regurgitation,” said Dr. Banbury. He also noted that pericardial valves should be considered appropriate for younger patients.




Related Links:
Edwards Lifesciences

Gold Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
VTE Prevention System
Flowtron ACS900
Mammo DR Retrofit Solution
DR Retrofit Mammography
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.